Shares of Allergy Therapeutics plc (LON:AGY - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 8.30 ($0.11) and last traded at GBX 8 ($0.11), with a volume of 575978 shares trading hands. The stock had previously closed at GBX 8.25 ($0.11).
Allergy Therapeutics Price Performance
The stock's fifty day moving average price is GBX 7.37 and its 200-day moving average price is GBX 6.85. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. The firm has a market cap of £393.21 million, a price-to-earnings ratio of -7.71, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
